Sign In
Buy KYTX
$8.43
+0.130 (+1.57%)
At Close: Jun 23, 2026
EMERYVILLE, Calif., June 22, 2026 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. (Nasdaq: KYTX), a late-stage clinical biopharmaceutical company developing cell therapies for patients with autoimmune
Kyverna Therapeutics vs. Vertex Pharmaceuticals: Which Drug Developer Stock Is a Better Buy in 2026?
02:34pm, Monday, 08'th Jun 2026
A clinical-stage innovator faces off against an established biotech powerhouse, each with distinct financials and risk profiles shaping their 2026 outlook.
Majority of patients met the American College of Rheumatology improvement criteria (ACR70) response by Week 36 Single-dose of miv-cel delivered deep B-cell depletion with evidence of immune reset Miv-
Kyverna Therapeutics Names Greg Martini as Chief Financial Officer
08:00am, Monday, 18'th May 2026
Veteran biopharma leader joins to help lead Kyverna's next phase of commercial growth Veteran biopharma leader joins to help lead Kyverna's next phase of commercial growth
Kyverna Therapeutics to Present at Upcoming Investor Conferences
08:00am, Thursday, 14'th May 2026
EMERYVILLE, Calif., May 14, 2026 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. (Nasdaq: KYTX), a late-stage clinical biopharmaceutical company focused on developing cell therapies for patients with a
Kyverna Therapeutics Announces Initiation of Rolling SPS BLA Submission and Reports First Quarter 2026 Financial Results
04:02pm, Tuesday, 12'th May 2026
Positive pre-BLA meeting with FDA alignment reached on KYSA-8 single-arm trial in stiff person syndrome (SPS); rolling BLA submission initiated
Kyverna Therapeutics Appoints Nadia Dac, Seasoned Commercial Leader in Neurology and Rare Disease, as Chief Commercial Officer
08:00am, Monday, 04'th May 2026
EMERYVILLE, Calif., May 04, 2026 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. (Nasdaq: KYTX), a late-stage clinical biopharmaceutical company focused on developing cell therapies for patients with a
Kyverna Therapeutics Showcases miv-cel Data in SPS, gMG; CEO Eyes First Autoimmune CAR-T BLA
01:06am, Monday, 27'th Apr 2026
Kyverna Therapeutics (NASDAQ: KYTX) highlighted new clinical data for its CD19-directed autologous CAR T-cell therapy mivocabtagene autoleucel (miv-cel), formerly KYV-101, during an American Academy o
Kyverna Therapeutics: 'Strong Buy' On Additional POC Of Miv-Cel In Myasthenia Gravis
03:31pm, Wednesday, 22'nd Apr 2026
Kyverna Therapeutics maintains a "Strong Buy" rating, driven by positive clinical data and upcoming regulatory milestones for miv-cel. Miv-cel achieved statistically significant endpoints in SPS and d
Single-dose of miv-cel achieved robust and durable improvements in mobility, reversed disability scores, and eliminated the need for chronic immunotherapies – outcomes not previously observed in SPS
Kyverna Therapeutics Positive Phase 2 Readout: Deep Responses, But Very Small Sample
07:30am, Tuesday, 21'st Apr 2026
Kyverna Therapeutics reported robust early Phase 2 miv-cel data in gMG, showing 100% response rates and deep, durable clinical improvements. KYTX's miv-cel offers rapid onset, potential for treatment-
100% of patients achieved rapid, sustained improvements across MG-ADL and QMG at 24 weeks, further increasing confidence in Phase 3 trial
Kyverna Therapeutics, Inc. (NASDAQ:KYTX) Receives $28.67 Average Price Target from Analysts
01:29am, Tuesday, 14'th Apr 2026
Kyverna Therapeutics, Inc. (NASDAQ: KYTX - Get Free Report) has earned a consensus recommendation of "Moderate Buy" from the five analysts that are currently covering the firm, MarketBeat.com reports.
Kyverna Therapeutics to Host Conference Call on New Data Across Neuroimmunology Franchise at AAN 2026
08:00am, Thursday, 09'th Apr 2026
EMERYVILLE, Calif., April 09, 2026 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. (Kyverna, Nasdaq: KYTX), a late-stage clinical biopharmaceutical company focused on developing cell therapies for pati
Kyverna Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results
04:02pm, Thursday, 26'th Mar 2026
Advancing first-to-market autoimmune CAR T opportunity in stiff person syndrome (SPS) with key launch preparation activities underway; BLA submission anticipated in 1H 2026
